Abstract:Russell Rosenberg, 1 Leslie Citrome, 2 Christopher L Drake 3 1 Neurotrials Research, Atlanta, GA, USA; 2 Department of Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, NY, USA; 3 Thomas Roth Sleep Disorders and Research Center, Henry Ford Health System, Detroit, MI, USA Correspondence: Russell Rosenberg Neurotrials Research, 5887 Glenridge Drive, Suite 400, Atlanta, GA, 30328, USA Tel +1 404 851 9934 Email Chronic insomnia disorder, which affects 6– 10% of the population, is diagnostically characterized by ongoing difficulties with initiating or maintaining sleep occurring at least three times per week, persisting for at least 3 months, and associated with daytime impairment. While chronic insomnia is often considered a condition primarily related to impaired sleep, the disorder can also adversely affect domains of physical and mental health, quality of life, and daytime function, which highlights the importance of treating the multidimensional sleep disorder. Owing to misperceptions about the safety and effectiveness of treatment options, many individuals with insomnia may not seek professional treatment, and alternatively use ineffective home remedies or over-the-counter medications to improve sleep. Some physicians may even believe that insomnia is remediated by simply having the patient "get more sleep". Unfortunately, treatment of insomnia is not always that simple. The disorder's complex underlying pathophysiology warrants consideration of different nonpharmacologic and pharmacologic treatment options. Indeed, recent insights gained from research into the pathophysiology of insomnia have facilitated development of newer treatment approaches with more efficacious outcomes. This narrative review provides a summary of the diagnostic criteria and pathophysiology of insomnia and its subtypes. Further, this review emphasizes new and emerging nonpharmacologic and pharmacologic treatments for chronic insomnia, including recent enhancements in approaches to cognitive behavioral therapy for insomnia (CBT-I) and the new dual orexin receptor antagonist (DORA) pharmacologics. These advances in treatment have expanded the treatment options and are likely to result in improved outcomes in patients with chronic insomnia. Keywords: dual orexin receptor antagonists, cognitive behavioral therapy-insomnia, insomnia subtype, hypnotic Insomnia disorder is described by the American Academy of Sleep Medicine (AASM) International Classification of Sleep Disorders, Third Edition, as having frequent and persistent difficulty initiating or maintaining sleep that results in general sleep dissatisfaction despite adequate opportunity for sleep. The sleep complaint is also accompanied by distress about poor sleep and/or impairment across various domains of functioning (eg, family, social, vocational, academic). 1 , 2 Insomnia is classified short-term if it persists less than 3 months and chronic if it persists at least 3 months and occurs at least three times per week. 1 , 2 Similar essential features of insomnia are described in the American Psychiatric Association (APA) Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition and include dissatisfaction with sleep quantity or quality with complaints of difficulty initiating or maintaining sleep. 3 The sleep disturbance must also cause clinically significant distress or impairments in social, occupational, or other important areas of functioning and may occur independently or during the course of another mental disorder or medical condition. 3 For many, insomnia becomes a long-term and persistent condition. A recent longitudinal study based on annual survey data demonstrated that 37.5% of participants with insomnia disorder at baseline continued to report insomnia symptoms through 5 years of follow-up. 4 The International Classification of Sleep Disorders, Third Edition and Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition also describe several secondary insomnias, which arise from co-occurring primary or causative conditions including mental disorders (eg, major depressive disorder), medical conditions (eg, pain), substance use, or another sleep disorder (eg, breathing-related sleep disorder). 1 , 3 Despite these insomnia subtypes, it is often difficult to differentiate between them clinically due to substantial symptom overlap between primary and secondary insomnia. Additionally, it is often difficult to assign causation to any single factor or establish the precise nature of the relationshi -Abstract Truncated-

C.06.01 is Schizophrenia a Progressive Brain Disease?

Pharmacological advances in the treatment of insomnia

Pharmacological Treatment of Chronic Insomnia

Melatonin and its analogs in insomnia and depression

Insomnia Management: A Review and Update

Chronic insomnia

Insomnia in Patients with Depression

Insomnia disorder: State of the science and challenges for the future

P.3.c.003 A Randomized, Controlled Study to Evaluate Quetiapine Fumarate in Improving Sleep Quality of Schizophrenia

[Hypnotics--state of the science]

Advances in the Treatment of Chronic Insomnia: A Narrative Review of New Nonpharmacologic and Pharmacologic Therapies

[Pharmacotherapies for insomnia]

Sleep, insomnia, and depression

Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysis

Polysomnographic features associated with clonazepam and melatonin treatment in isolated REM sleep behavior disorder: Time for new therapeutic approaches?

New and emerging pharmacotherapeutic approaches for insomnia

Depression and insomnia: questions of cause and effect

Does Effective Management of Sleep Disorders Reduce Depressive Symptoms and the Risk of Depression?

Efficacy of melatonin and ramelteon for the acute and long‐term management of insomnia disorder in adults: A systematic review and meta‐analysis

[Sleep disorders in patients with a neurocognitive disorder]

Insomnia